Ranolazine for Angina in Hypertrophic Cardiomyopathy
Ranolazine is an antianginal and works by inhibiting late-sodium current (INaL). However, its use is limited mostly to patients with coronary artery disease. However, literature has shown its potential benefit in relieving angina in hypertrophic cardiomyopathy. Hereby, we discuss two cases where ran...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Case Reports in Cardiology |
| Online Access: | http://dx.doi.org/10.1155/2018/5142572 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850163670846275584 |
|---|---|
| author | Akhtar Amin Bernard Kim |
| author_facet | Akhtar Amin Bernard Kim |
| author_sort | Akhtar Amin |
| collection | DOAJ |
| description | Ranolazine is an antianginal and works by inhibiting late-sodium current (INaL). However, its use is limited mostly to patients with coronary artery disease. However, literature has shown its potential benefit in relieving angina in hypertrophic cardiomyopathy. Hereby, we discuss two cases where ranolazine led to improvement in angina refractory to beta-blockers. In conclusion, ranolazine can be considered as a potential antianginal drug in patients with hypertrophic cardiomyopathy refractory to beta-blockers. |
| format | Article |
| id | doaj-art-ed631d669d5a4620860ecb5233a2a3b5 |
| institution | OA Journals |
| issn | 2090-6404 2090-6412 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Cardiology |
| spelling | doaj-art-ed631d669d5a4620860ecb5233a2a3b52025-08-20T02:22:10ZengWileyCase Reports in Cardiology2090-64042090-64122018-01-01201810.1155/2018/51425725142572Ranolazine for Angina in Hypertrophic CardiomyopathyAkhtar Amin0Bernard Kim1Department of Internal Medicine, Rutgers New Jersey Medical School, Newark, NJ, USADepartment of Cardiology, Hackensack University Medical Center, Hackensack, NJ, USARanolazine is an antianginal and works by inhibiting late-sodium current (INaL). However, its use is limited mostly to patients with coronary artery disease. However, literature has shown its potential benefit in relieving angina in hypertrophic cardiomyopathy. Hereby, we discuss two cases where ranolazine led to improvement in angina refractory to beta-blockers. In conclusion, ranolazine can be considered as a potential antianginal drug in patients with hypertrophic cardiomyopathy refractory to beta-blockers.http://dx.doi.org/10.1155/2018/5142572 |
| spellingShingle | Akhtar Amin Bernard Kim Ranolazine for Angina in Hypertrophic Cardiomyopathy Case Reports in Cardiology |
| title | Ranolazine for Angina in Hypertrophic Cardiomyopathy |
| title_full | Ranolazine for Angina in Hypertrophic Cardiomyopathy |
| title_fullStr | Ranolazine for Angina in Hypertrophic Cardiomyopathy |
| title_full_unstemmed | Ranolazine for Angina in Hypertrophic Cardiomyopathy |
| title_short | Ranolazine for Angina in Hypertrophic Cardiomyopathy |
| title_sort | ranolazine for angina in hypertrophic cardiomyopathy |
| url | http://dx.doi.org/10.1155/2018/5142572 |
| work_keys_str_mv | AT akhtaramin ranolazineforanginainhypertrophiccardiomyopathy AT bernardkim ranolazineforanginainhypertrophiccardiomyopathy |